XML 124 R2.htm IDEA: XBRL DOCUMENT v3.24.1.u1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure        
Pay vs Performance Disclosure, Table
Year
Summary
Compensation
Table Total
for CEO(1)
($)
Compensation
Actually Paid
to CEO(2)
($)
Average
Summary
Compensation
Table Total
for Non-CEO
Named
Executive
Officers(3)
($)
Average
Compensation
Actually
Paid to
Non-CEO
Named
Executive
Officers
($)		Value of Initial Fixed
$100 Investment
Based On:
($)		Net Loss
($ thousands)
Company-
Selected
Measure:
Revenue
($ thousands)(5)
Total
Shareholder
Return
Peer Group
Total
Shareholder
Return(4)
202311,613,736 9,400,898 4,935,878 3,702,389 26 143 (220,368)2,602,415 
202210,876,053 (2,755,173)8,211,732 3,613,853 28 140 (13,659,531)2,406,840 
202111,637,898 (4,486,255)3,776,044 (1,412,623)110 143 (428,793)2,032,707 
20208,455,584 54,668,602 2,614,048 12,280,174 239 113 (485,136)1,093,962 
      
Company Selected Measure Name revenue      
Named Executive Officers, Footnote The dollar amounts reported in this column are the amounts of total compensation reported for Mr. Gorevic, our former CEO for each corresponding year in the “Total” column of the Summary Compensation Table.      
Peer Group Issuers, Footnote The peer group used for calculating Peer Group Total Shareholder Return is the S&P 500 Health Care Index.      
PEO Total Compensation Amount $ 11,613,736 $ 10,876,053 $ 11,637,898 $ 8,455,584
PEO Actually Paid Compensation Amount $ 9,400,898 (2,755,173) (4,486,255) 54,668,602
Adjustment To PEO Compensation, Footnote The CEO in each covered year is Mr. Gorevic. The CEO Summary Compensation Table to compensation actually paid reconciliation is summarized in the following table:
2023202220212020
Summary Compensation Table Total Compensation$11,613,736 $10,876,053 $11,637,898 $8,455,584 
Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year(10,000,006)(10,000,020)(10,000,131)(6,800,017)
Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year7,779,810 1,593,442 3,762,671 14,745,250 
Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years(93,277)(3,507,008)(10,210,349)22,192,866 
Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year— — — — 
Change in Fair Value as of Vesting Date of Option Awards and
Stock Awards Granted in Prior Fiscal Years For Which Applicable
Vesting Conditions Were Satisfied During Fiscal Year		100,635 (1,717,640)323,656 16,074,919 
Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year— — — — 
Compensation actually paid$9,400,898 $(2,755,173)$(4,486,255)$54,668,602 
      
Non-PEO NEO Average Total Compensation Amount $ 4,935,878 8,211,732 3,776,044 2,614,048
Non-PEO NEO Average Compensation Actually Paid Amount $ 3,702,389 3,613,853 (1,412,623) 12,280,174
Adjustment to Non-PEO NEO Compensation Footnote The non-CEO named executive officers for whom the average compensation is presented in this table are: for 2023, Ms. Murthy and Messrs. Kornwasser, Waters and Vandervoort; for 2022, Ms. Murthy, Dr. Jensen and Messrs. Kornwasser and Waters; for 2021, Ms. Murthy, Dr. Jensen and Messrs. David Sides, Turitz and Vandervoort; and for 2020, Mmes. Murthy and Verstraete and Messrs. Sides and Vandervoort. Mr. Sides is our former Chief Operating Officer and resigned from the Company effective on September 21, 2021. Dr. Jensen is our former Chief Innovation Officer and resigned from the Company effective on December 1, 2023.
2023202220212020
Summary Compensation Table Total Compensation$4,935,878 $8,211,732 $3,776,044 $2,614,048 
Grant Date Fair Value of Option Awards and Stock Awards Granted in Fiscal Year(4,087,486)(7,249,976)(3,041,445)(1,700,036)
Fair Value at Fiscal Year-End of Outstanding and Unvested Option Awards and Stock Awards Granted in Fiscal Year3,179,986 3,668,043 1,058,324 3,686,363 
Change in Fair Value of Outstanding and Unvested Option Awards and Stock Awards Granted in Prior Fiscal Years(211,897)(693,095)(1,461,413)4,650,682 
Fair Value at Vesting of Option Awards and Stock Awards Granted in Fiscal Year That Vested During Fiscal Year— — — — 
Change in Fair Value as of Vesting Date of Option Awards and Stock Awards Granted in Prior Fiscal Years For Which Applicable Vesting Conditions Were Satisfied During Fiscal Year(114,092)(322,851)(219,721)3,029,117 
Fair Value as of Prior Fiscal Year-End of Option Awards and Stock Awards Granted in Prior Fiscal Years That Failed to Meet Applicable Vesting Conditions During Fiscal Year— — (1,524,412)— 
Compensation actually paid$3,702,389 $3,613,853 $(1,412,623)$12,280,174 
      
Compensation Actually Paid vs. Total Shareholder Return
Teladoc Health, Inc. & Peer TSR vs. Compensation Actually Paid
28037546522067
gfx_barLegend_CEO.jpg 
CEO CAP ($M)
gfx_barLegend_average.jpg 
Average NEO CAP ($M)
gfx_barLegend_TDOC.jpg 
TDOC
gfx_barLegend_S&P.jpg 
S&P 500 Health Care Sector
      
Compensation Actually Paid vs. Net Income
Teladoc Health, Inc. Net loss vs. Compensation Actually Paid
28037546522099
gfx_barLegend_CEO.jpg 
CEO CAP ($M)
gfx_barLegend_average.jpg 
Average NEO CAP ($M)
gfx_barLegend_TDOC2.jpg 
TDOC Net Loss
      
Compensation Actually Paid vs. Company Selected Measure
Teladoc Health, Inc. Revenue vs. Compensation Actually Paid
28037546522112
gfx_barLegend_CEO.jpg 
CEO CAP ($M)
gfx_barLegend_average.jpg 
Average NEO CAP ($M)
gfx_barLegend_TDOC2.jpg 
TDOC Revenue
      
Total Shareholder Return Vs Peer Group
Teladoc Health, Inc. & Peer TSR vs. Compensation Actually Paid
28037546522067
gfx_barLegend_CEO.jpg 
CEO CAP ($M)
gfx_barLegend_average.jpg 
Average NEO CAP ($M)
gfx_barLegend_TDOC.jpg 
TDOC
gfx_barLegend_S&P.jpg 
S&P 500 Health Care Sector
      
Tabular List, Table
Measure Explanation
Financial Measures Revenue
Measures our top-line growth
Adjusted EBITDA
A non-GAAP measure that consists of net loss before interest income; interest expense; other (income) expense, net, including foreign exchange gains or losses; provision for income taxes; depreciation; amortization; goodwill impairment; stock-based compensation; restructuring costs; and acquisition, integration, and transformation costs
Net Income
Measures our bottom-line growth
Non-Financial Measures Corporate health
Consists of three components intended to improve our human capital management: voluntary attrition by employees, building a more diverse leadership team, and employee satisfaction
      
Total Shareholder Return Amount $ 26 28 110 239
Peer Group Total Shareholder Return Amount 143 140 143 113
Net Income (Loss) $ (220,368,000) $ (13,659,531,000) $ (428,793,000) $ (485,136,000)
Company Selected Measure Amount 2,602,415,000 2,406,840,000 2,032,707,000 1,093,962,000
PEO Name Mr. Gorevic      
Additional 402(v) Disclosure We have determined that revenue is the financial performance measure that, in our assessment, represents the most important performance measure (that is not otherwise required to be disclosed in the table) used to link compensation actually paid to our named executive officers, for the most recently completed fiscal year, to company performance.      
Measure:: 1        
Pay vs Performance Disclosure        
Name Revenue      
Measure:: 2        
Pay vs Performance Disclosure        
Name Adjusted EBITDA      
Measure:: 3        
Pay vs Performance Disclosure        
Name Net Income      
Measure:: 4        
Pay vs Performance Disclosure        
Name Corporate health      
PEO | Reported Grant Date Fair Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ (10,000,006) $ (10,000,020) $ (10,000,131) $ (6,800,017)
PEO | Equity Awards Granted During Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 7,779,810 1,593,442 3,762,671 14,745,250
PEO | Equity Awards Granted During Prio Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (93,277) (3,507,008) (10,210,349) 22,192,866
PEO | Equity Awards Granted During Year, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
PEO | Equity Awards Granted During Prior Year, Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 100,635 (1,717,640) 323,656 16,074,919
PEO | Equity Awards Granted During Prior Year, Failed To Meet Applicable Vesting Conditions [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
Non-PEO NEO | Reported Grant Date Fair Value [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (4,087,486) (7,249,976) (3,041,445) (1,700,036)
Non-PEO NEO | Equity Awards Granted During Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 3,179,986 3,668,043 1,058,324 3,686,363
Non-PEO NEO | Equity Awards Granted During Prio Year, Unvested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (211,897) (693,095) (1,461,413) 4,650,682
Non-PEO NEO | Equity Awards Granted During Year, Vested [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount 0 0 0 0
Non-PEO NEO | Equity Awards Granted During Prior Year, Vested During Year [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount (114,092) (322,851) (219,721) 3,029,117
Non-PEO NEO | Equity Awards Granted During Prior Year, Failed To Meet Applicable Vesting Conditions [Member]        
Pay vs Performance Disclosure        
Adjustment to Compensation, Amount $ 0 $ 0 $ (1,524,412) $ 0